<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFTRIAXONEÂ - ceftriaxone sodiumÂ injection, powder, for solutionÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Ceftriaxone for Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis">R<span class="Sub">x</span> only</span></span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Ceftriaxone for Injection, USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6<span class="Italics"><span class="Emphasis">R</span></span>,7<span class="Italics"><span class="Emphasis">R</span></span>)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-<span class="Italics"><span class="Emphasis">as</span></span>-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7<span class="Sup">2</span>-(<span class="Italics"><span class="Emphasis">Z</span></span>)-(<span class="Italics"><span class="Emphasis">O</span></span>-methyloxime), disodium salt, sesquaterhydrate.</p>
<p>The chemical formula of ceftriaxone sodium is C<span class="Sub">18</span>H<span class="Sub">16</span>N<span class="Sub">8</span>Na<span class="Sub">2</span>O<span class="Sub">7</span>S<span class="Sub">3</span>â€¢3.5 H<span class="Sub">2</span>O. It has a calculated molecular weight of 661.59 and the following structural formula:</p>
<p>Â <img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0faaee8c-30f6-4715-a9b6-7978da7c1ec8&amp;name=MM1.jpg"></p>
<p>Ceftriaxone for Injection, USP is a white to yellowish-orange crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of Ceftriaxone for Injection, USP solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.</p>
<p>Ceftriaxone for Injection, USP contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Average plasma concentrations of ceftriaxone following a single 30 minute intravenous (IV) infusion of a 0.5, 1 or 2 gm dose and intramuscular (IM) administration of a single 0.5 (250 mg/mL or 350 mg/mL concentrations) or 1 gm dose in healthy subjects are presented in <span class="Bold"><span class="Emphasis">Table 1</span></span>.</p>
<table>
<caption><span>Table 1 Ceftriaxone Plasma Concentrations After Single Dose Administration </span></caption>
<tbody class="Headless">
<tr class="First">
<td><p class="First">Dose/Route</p></td>
<td><p class="First">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Average Plasma Concentrations (mcg/mL)</p></td>
</tr>
<tr>
<td><p class="First">Â </p></td>
<td><p class="First">0.5 hr</p></td>
<td><p class="First">1 hr</p></td>
<td><p class="First">2 hr</p></td>
<td><p class="First">4 hr</p></td>
<td><p class="First">6 hr</p></td>
<td><p class="First">8 hr</p></td>
<td><p class="First">12 hr</p></td>
<td><p class="First">16 hr</p></td>
<td><p class="First">24 hr</p></td>
</tr>
<tr>
<td><p class="First">0.5 gm IV*</p></td>
<td><p class="First">82</p></td>
<td><p class="First">59</p></td>
<td><p class="First">48</p></td>
<td><p class="First">37</p></td>
<td><p class="First">29</p></td>
<td><p class="First">23</p></td>
<td><p class="First">15</p></td>
<td><p class="First">10</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">0.5 gm IM<br>
Â  250 mg/mL</p></td>
<td><p class="First">22</p></td>
<td><p class="First">33</p></td>
<td><p class="First">38</p></td>
<td><p class="First">35</p></td>
<td><p class="First">30</p></td>
<td><p class="First">26</p></td>
<td><p class="First">16</p></td>
<td><p class="First">ND</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">0.5 gm IM<br>
Â  350 mg/mL</p></td>
<td><p class="First">Â <br>
20</p></td>
<td><p class="First">Â <br>
32</p></td>
<td><p class="First">Â <br>
38</p></td>
<td><p class="First">34</p></td>
<td><p class="First">31</p></td>
<td><p class="First">24</p></td>
<td><p class="First">16</p></td>
<td><p class="First">ND</p></td>
<td><p class="First">Â <br>
5</p></td>
</tr>
<tr>
<td><p class="First">1 gm IV*</p></td>
<td><p class="First">151</p></td>
<td><p class="First">111</p></td>
<td><p class="First">88</p></td>
<td><p class="First">67</p></td>
<td><p class="First">53</p></td>
<td><p class="First">43</p></td>
<td><p class="First">28</p></td>
<td><p class="First">18</p></td>
<td><p class="First">9</p></td>
</tr>
<tr>
<td><p class="First">1 gm IM</p></td>
<td><p class="First">40</p></td>
<td><p class="First">68</p></td>
<td><p class="First">76</p></td>
<td><p class="First">68</p></td>
<td><p class="First">56</p></td>
<td><p class="First">44</p></td>
<td><p class="First">29</p></td>
<td><p class="First">ND</p></td>
<td><p class="First">ND</p></td>
</tr>
<tr>
<td><p class="First">2 gm IV*</p></td>
<td><p class="First">257</p></td>
<td><p class="First">192</p></td>
<td><p class="First">154</p></td>
<td><p class="First">117</p></td>
<td><p class="First">89</p></td>
<td><p class="First">74</p></td>
<td><p class="First">46</p></td>
<td><p class="First">31</p></td>
<td><p class="First">15</p></td>
</tr>
<tr class="Last"><td><p class="First">*IV doses were infused at a constant rate over 30 minutes.<br>
Â ND = Not determined.</p></td></tr>
</tbody>
</table>
<p>Ceftriaxone was completely absorbed following IM administration with mean maximum plasma concentrations occurring between 2 and 3 hours post-dose. Multiple IV or IM doses ranging from 0.5 to 2 gm at 12 to 24 hour intervals resulted in 15% to 36% accumulation of ceftriaxone above single dose values.</p>
<p>Ceftriaxone concentrations in urine are shown in <span class="Bold"><span class="Emphasis">Table 2</span></span>.</p>
<table>
<caption><span>Table 2 Urinary Concentrations of Ceftriaxone After Single Dose Administration </span></caption>
<tbody class="Headless">
<tr class="First">
<td><p class="First">Dose/Route</p></td>
<td><p class="First">Average Urinary Concentrations (mcg/mL)</p></td>
</tr>
<tr>
<td><p class="First">Â </p></td>
<td><p class="First">0 to 2 hr</p></td>
<td><p class="First">2 to 4 hr</p></td>
<td><p class="First">4 to 8 hr</p></td>
<td><p class="First">8 to12 hr</p></td>
<td><p class="First">12 to 24 hr</p></td>
<td><p class="First">24 to 48 hr</p></td>
</tr>
<tr>
<td><p class="First">0.5 gm IV</p></td>
<td><p class="First">526</p></td>
<td><p class="First">366</p></td>
<td><p class="First">142</p></td>
<td><p class="First">87</p></td>
<td><p class="First">70</p></td>
<td><p class="First">15</p></td>
</tr>
<tr>
<td><p class="First">0.5 gm IM</p></td>
<td><p class="First">115</p></td>
<td><p class="First">425</p></td>
<td><p class="First">308</p></td>
<td><p class="First">127</p></td>
<td><p class="First">96</p></td>
<td><p class="First">28</p></td>
</tr>
<tr>
<td><p class="First">1 gm IV</p></td>
<td><p class="First">995</p></td>
<td><p class="First">855</p></td>
<td><p class="First">293</p></td>
<td><p class="First">147</p></td>
<td><p class="First">132</p></td>
<td><p class="First">32</p></td>
</tr>
<tr>
<td><p class="First">1 gm IM</p></td>
<td><p class="First">504</p></td>
<td><p class="First">628</p></td>
<td><p class="First">418</p></td>
<td><p class="First">237</p></td>
<td><p class="First">ND</p></td>
<td><p class="First">ND</p></td>
</tr>
<tr>
<td><p class="First">2 gm IV</p></td>
<td><p class="First">2692</p></td>
<td><p class="First">1976</p></td>
<td><p class="First">757</p></td>
<td><p class="First">274</p></td>
<td><p class="First">198</p></td>
<td><p class="First">40</p></td>
</tr>
<tr class="Last"><td><p class="First">ND = Not determined.</p></td></tr>
</tbody>
</table>
<p>Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. After a 1 gm IV dose, average concentrations of ceftriaxone, determined from 1 to 3 hours after dosing, were 581 mcg/mL in the gallbladder bile, 788 mcg/mL in the common duct bile, 898 mcg/mL in the cystic duct bile, 78.2 mcg/gm in the gallbladder wall and 62.1 mcg/mL in the concurrent plasma.</p>
<p>Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of &lt;25 mcg/mL to a value of 85% bound at 300 mcg/mL. Ceftriaxone crosses the blood placenta barrier.</p>
<p>The average values of maximum plasma concentration, elimination half-life, plasma clearance and volume of distribution after a 50 mg/kg IV dose and after a 75 mg/kg IV dose in pediatric patients suffering from <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span> are shown in <span class="Bold"><span class="Emphasis">Table 3</span></span>. Ceftriaxone penetrated the inflamed meninges of infants and pediatric patients; CSF concentrations after a 50 mg/kg IV dose and after a 75 mg/kg IV dose are also shown in <span class="Bold"><span class="Emphasis">Table 3</span></span>.</p>
<table>
<caption><span>Table 3 Average Pharmacokinetic Parameters of Ceftriaxone in Pediatric Patients With <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></span></caption>
<tbody class="Headless">
<tr class="First">
<td><p class="First">Â </p></td>
<td><p class="First">50 mg/kg IV</p></td>
<td><p class="First">75 mg/kg IV</p></td>
</tr>
<tr>
<td><p class="First">Maximum Plasma Concentrations (mcg/mL)</p></td>
<td><p class="First">216</p></td>
<td><p class="First">275</p></td>
</tr>
<tr>
<td><p class="First">Elimination Half-life (hr)</p></td>
<td><p class="First">4.6</p></td>
<td><p class="First">4.3</p></td>
</tr>
<tr>
<td><p class="First">Plasma Clearance (mL/hr/kg)</p></td>
<td><p class="First">49</p></td>
<td><p class="First">60</p></td>
</tr>
<tr>
<td><p class="First">Volume of Distribution (mL/kg)</p></td>
<td><p class="First">338</p></td>
<td><p class="First">373</p></td>
</tr>
<tr>
<td><p class="First">CSF Concentration-inflamed meninges (mcg/mL)</p></td>
<td><p class="First">5.6</p></td>
<td><p class="First">6.4</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Range (mcg/mL)</p></td>
<td><p class="First">1.3 to 18.5</p></td>
<td><p class="First">1.3 to 44</p></td>
</tr>
<tr class="Last">
<td><p class="First">Â Â Â  Time after dose (hr)</p></td>
<td><p class="First">3.7 (Â± 1.6)</p></td>
<td><p class="First">3.3 (Â± 1.4)</p></td>
</tr>
</tbody>
</table>
<p>Compared to that in healthy adult subjects, the pharmacokinetics of ceftriaxone were only minimally altered in elderly subjects and in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or hepatic dysfunction (<span class="Bold"><span class="Emphasis">Table 4</span></span>); therefore, dosage adjustments are not necessary for these patients with ceftriaxone dosages up to 2 gm per day. Ceftriaxone was not removed to any significant extent from the plasma by hemodialysis; in six of 26 dialysis patients, the elimination rate of ceftriaxone was markedly reduced.</p>
<table>
<caption><span>Table 4 Average Pharmacokinetic Parameters of Ceftriaxone in Humans </span></caption>
<tbody class="Headless">
<tr class="First">
<td><p class="First">Subject Group</p></td>
<td><p class="First">Elimination<br>
Half-Life<br>
(hr)</p></td>
<td><p class="First">Plasma<br>
Clearance<br>
(L/hr)</p></td>
<td>
<p class="First">Volume of</p>
<p>Distribution<br>
(L)</p>
</td>
</tr>
<tr>
<td><p class="First">Healthy Subjects</p></td>
<td><p class="First">5.8 to 8.7</p></td>
<td><p class="First">0.58 to 1.45</p></td>
<td><p class="First">5.8 to 13.5</p></td>
</tr>
<tr>
<td><p class="First">Elderly Subjects (mean age, 70.5 yr)</p></td>
<td><p class="First">8.9</p></td>
<td><p class="First">0.83</p></td>
<td><p class="First">10.7</p></td>
</tr>
<tr>
<td><p class="First">Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p></td>
<td><p class="First">Â </p></td>
<td><p class="First">Â </p></td>
<td><p class="First">Â </p></td>
</tr>
<tr>
<td><p class="First">Â Â Â  Hemodialysis Patients (0 to 5 mL/min)*</p></td>
<td><p class="First">14.7</p></td>
<td><p class="First">0.65</p></td>
<td><p class="First">13.7</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â  Severe (5 to 15 mL/min)</p></td>
<td><p class="First">15.7</p></td>
<td><p class="First">0.56</p></td>
<td><p class="First">12.5</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â  Moderate (16 to 30 mL/min)</p></td>
<td><p class="First">11.4</p></td>
<td><p class="First">0.72</p></td>
<td><p class="First">11.8</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â  Mild (31 to 60 mL/min)</p></td>
<td><p class="First">12.4</p></td>
<td><p class="First">0.7</p></td>
<td><p class="First">13.3</p></td>
</tr>
<tr>
<td><p class="First">Patients With Liver Disease</p></td>
<td><p class="First">8.8</p></td>
<td><p class="First">1.1</p></td>
<td><p class="First">13.6</p></td>
</tr>
<tr class="Last"><td><p class="First">* Creatinine clearance.</p></td></tr>
</tbody>
</table>
<p>The elimination of ceftriaxone is not altered when ceftriaxone for injection isÂ co-administered with probenecid.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics in the Middle Ear Fluid</span></span></p>
<p>In one study, total ceftriaxone concentrations (bound and unbound) were measured in middle ear fluid obtained during the insertion of tympanostomy tubes in 42 pediatric patients with <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. Sampling times were from 1 to 50 hours after a single intramuscular injection of 50 mg/kg of ceftriaxone. Mean (Â± SD) ceftriaxone levels in the middle ear reached a peak of 35 (Â± 12) mcg/mL at 24 hours, and remained at 19 (Â± 7) mcg/mL at 48 hours. Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma proteins. The extent of binding to proteins in the middle ear fluid is unknown.</p>
<p><span class="Bold"><span class="Emphasis">Interaction with Calcium:</span></span> Two <span class="Italics"><span class="Emphasis">in vitro</span></span> studies, one using adult plasma and the other neonatal plasma from umbilical cord blood have been carried out to assess interaction of ceftriaxone and calcium. Ceftriaxone concentrations up to 1 mM (in excess of concentrations achieved <span class="Italics"><span class="Emphasis">in vivo </span></span>following administration of 2 grams ceftriaxone infused over 30 minutes) were used in combination with calcium concentrations up to 12 mM (48 mg/dL). Recovery of ceftriaxone from plasma was reduced with calcium concentrations of 6 mM (24 mg/dL) or higher in adult plasma or 4 mM (16 mg/dL) or higher in neonatal plasma. This may be reflective of ceftriaxone-calcium precipitation.</p>
<p><span class="Bold"><span class="Emphasis">Microbiology:</span></span></p>
<p>The bactericidal activity of ceftriaxone results from inhibition of cell wall synthesis. Ceftriaxone has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria.</p>
<p>In an <span class="Italics"><span class="Emphasis">in vitro </span></span>study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. </p>
<p>Ceftriaxone has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics"><span class="Emphasis">in vitro</span></span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> described in the <span class="Bold"><span class="Emphasis"><a href="#f6f5ae63-102e-4f0e-b877-27c84b697992">INDICATIONS AND USAGE</a>Â </span></span>section.</p>
<p>Aerobic gram-negative microorganisms:<br><span class="Italics"><span class="Emphasis">Acinetobacter calcoaceticus<br>
Enterobacter aerogenes<br>
Enterobacter cloacae<br>
Escherichia coli<br>
Haemophilus influenzae</span></span> (including ampicillin-resistant and beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics"><span class="Emphasis">Haemophilus parainfluenzae<br>
Klebsiella oxytoca<br>
Klebsiella pneumoniae<br>
Moraxella catarrhalis</span></span> (including beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics"><span class="Emphasis">Morganella morganii<br>
Neisseria gonorrhoeae</span></span> (including penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics"><span class="Emphasis">Neisseria meningitidis<br>
Proteus mirabilis<br>
Proteus vulgaris<br>
Serratia marcescens</span></span>Â </p>
<p>Ceftriaxone is also active against many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Pseudomonas aeruginosa.</span></span>Â </p>
<p>NOTE: Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the above organisms that are resistant to multiple antibiotics, e.g., penicillins, cephalosporins, and aminoglycosides, are susceptible to ceftriaxone.</p>
<p>Aerobic gram-positive microorganisms:<br><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics"><span class="Emphasis">Staphylococcus epidermidis<br>
Streptococcus pneumoniae<br>
Streptococcus pyogenes</span></span>Â <br>
Viridans group streptococci</p>
<p>NOTE: Methicillin-resistant staphylococci are resistant to cephalosporins, including ceftriaxone. Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of Group D streptococci and enterococci, e.g., <span class="Italics"><span class="Emphasis">Enterococcus</span></span> (<span class="Italics"><span class="Emphasis">Streptococcus</span></span>)<span class="Italics"><span class="Emphasis"> faecalis,</span></span> are resistant.</p>
<p>Anaerobic microorganisms:<br><span class="Italics"><span class="Emphasis">Bacteroides fragilis<br>
Clostridium</span></span> species<br><span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species</p>
<p>NOTE: Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Clostridium difficile</span></span> are resistant.</p>
<p>The following <span class="Italics"><span class="Emphasis">in vitro</span></span> data are available, <span class="Bold"><span class="Emphasis"><span class="Underline">but their clinical significance is unknown</span></span></span>. Ceftriaxone exhibits <span class="Italics"><span class="Emphasis">in vitro</span></span> minimal inhibitory concentrations (MICs) of â‰¤1 mcg/mL or less against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, however, the safety and effectiveness of ceftriaxone in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p>Aerobic gram-negative microorganisms:<br><span class="Italics"><span class="Emphasis">Citrobacter diversus<br>
Citrobacter freundii<br>
Providencia</span></span> species (including <span class="Italics"><span class="Emphasis">Providencia rettgeri</span></span>)<br><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span></span> species (including <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi</span></span>)<br><span class="Italics"><span class="Emphasis">Shigella</span></span> species</p>
<p>Aerobic gram-positive microorganisms:<br><span class="Italics"><span class="Emphasis">Streptococcus agalactiae</span></span>Â </p>
<p>Anaerobic microorganisms:<br><span class="Italics"><span class="Emphasis">Prevotella</span></span> (<span class="Italics"><span class="Emphasis">Bacteroides</span></span>)<span class="Italics"><span class="Emphasis"> bivius<br>
Porphyromonas</span></span> (<span class="Italics"><span class="Emphasis">Bacteroides</span></span>)<span class="Italics"><span class="Emphasis"> melaninogenicus</span></span>Â </p>
<p><span class="Bold"><span class="Emphasis">Susceptibility Tests</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Dilution Techniques</span></span></span><span class="Italics"><span class="Emphasis">: </span></span>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.<span class="Sup">1</span> Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ceftriaxone powder. For details of susceptibility test methodologies,, the most recent documents of the Clinical and Laboratory Standards Institute (CLSI) for antimicrobial susceptibility testing<span class="Sup">1-3 </span>should be consulted.</p>
<p>The MIC values for aerobic organisms should be interpreted according to the following criteria:</p>
<p>For <span class="Italics"><span class="Emphasis">Enterobacteriaceae:</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤1<br>
2<br>
â‰¥4</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>The following interpretive criteria should be used when testing <span class="Italics"><span class="Emphasis">Haemophilus</span></span> species using Haemophilus Test Media (HTM).</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤2</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>The absence of resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than â€œSusceptibleâ€?. <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding results suggestive of a â€œNonsusceptibleâ€? category should be submitted to a reference laboratory for further testing.</p>
<p>The following interpretive criteria should be used when testing <span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae</span></span> when using GC agar base and 1% defined growth supplement.</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤0.25</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>The following interpretive criteria<span class="Sup">4 </span>should be used when testing <span class="Italics"><span class="Emphasis">Neisseria meningitidis </span></span>on Mueller-Hinton agar with 5% defribrinated sheep blood.</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤0.12</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>The absence of resistant neisserial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than â€œSusceptibleâ€?. <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding results suggestive of a â€œNonsusceptibleâ€? category should be submitted to a reference laboratory for further testing.</p>
<p>When testing <span class="Italics"><span class="Emphasis">Staphylococcus aureus </span></span>(methicillin-susceptible, MSSA) the following interpretive criteria should be applied: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤4<br>
8<br>
â‰¥16</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>For <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, a daily dose of 2 to 4 grams should be administered to achieve &gt;90% target attainment (see <span class="Bold"><span class="Emphasis"><a href="#b3044a83-f607-44c5-9973-6cb59c22411a">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>The following interpretive criteria should be used when testing <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae </span></span>using Mueller-Hinton broth with 2 to 5% lysed horse blood: </p>
<p><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span>: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤0.5<br>
1<br>
â‰¥2</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>Non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤1<br>
Â  2<br>
â‰¥4</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>For Î²-hemolytic streptococci the following interpretive criteria should be used when testing on cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤0.5</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>For the Viridians Group streptococci the following interpretive criteria should be applied: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤1<br>
Â  2<br>
â‰¥4</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the results should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of the drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standardized ceftriaxone powder should provide the following MIC values:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Microorganism</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">ATCC<span class="Sup">Â®</span>#</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Escherichia coli</span></span></p></td>
<td><p class="First">25922</p></td>
<td><p class="First">0.03 to Â 0.12</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span></p></td>
<td><p class="First">29213</p></td>
<td><p class="First">1 to 8*</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Pseudomonas aeruginosa</span></span></p></td>
<td><p class="First">27853</p></td>
<td><p class="First">8 to 64</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Haemophilus influenzae</span></span></p></td>
<td><p class="First">49247</p></td>
<td><p class="First">0.06 to 0.25</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae</span></span></p></td>
<td><p class="First">49226</p></td>
<td><p class="First">0.004 to 0.015</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span></p></td>
<td><p class="First">49619</p></td>
<td><p class="First">0.03 to 0.12</p></td>
</tr>
<tr class="Last"><td><p class="First">*A bimodal distribution of MICs results at the extremes of the acceptable range should be suspect and control validity should be verified with data from other control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p></td></tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">Diffusion Techniques:</span></span></span> Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">3</span> requires the use of standardized inoculum concentrations. This procedure uses paper discs impregnated with 30 mcg of ceftriaxone to test the susceptibility of microorganisms to ceftriaxone.</p>
<p>Reports from the laboratory providing results of the standard single-disc susceptibility test with a 30 mcg ceftriaxone disc should be interpreted according to the following criteria for aerobic organisms:</p>
<p>For <span class="Italics"><span class="Emphasis">Enterobacteriaceae:</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥23<br>
20 to 22<br>
â‰¤19</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>When testing <span class="Italics"><span class="Emphasis">Haemophilus influenzae </span></span>on Haemophilus Test Media (HTM), the following interpretive criteria should be used:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥26</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>The absence of resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than â€œSusceptibleâ€?. <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding results suggestive of a â€œNonsusceptibleâ€? category should be submitted to a reference laboratory-for further testing.</p>
<p>The following interpretive criteria should be used when testing <span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae</span></span> when using GC agar base and 1% defined growth supplement:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥35</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>For Neisseria meningitidis, the following disc diffusion criteria apply:<span class="Sup">5</span></p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥34</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>For Straphylococcus aureus (methicillin-susceptibile, MSSA), the following interpretive criteria apply:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥21<br>
14 to 20<br>
â‰¤13</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>The following interpretive criteria should be used when testing ÃŸ-hemolytic streptococci using Mueller-Hinton agar supplemented with 5% sheep blood incubated in 5% CO<span class="Sub">2</span>: </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥24</p></td>
<td><p class="First">(S) Susceptible</p></td>
</tr>
</tbody></table>
<p>For the Viridians Group streptococci the following criteria apply:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone diameter (mm)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥27<br>
25 to 26<br>
â‰¤24</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disc test with the MIC for ceftriaxone.</p>
<p>Disc diffusion interpretive criteria for ceftriaxone discs against <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span> are not available, however, isolates of pneumococci with oxacillin zone diameters of &gt;20 mm are susceptible (MIC â‰¤0.06 mcg/mL) to penicillin and can be considered susceptible to ceftriaxone. <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span> isolates should not be reported as penicillin (ceftriaxone) resistant or intermediate based solely on an oxacillin zone diameter ofÂ  â‰¤19 mm. The ceftriaxone MIC should be determined for those isolates with oxacillin zone diameters â‰¤19 mm.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg ceftriaxone disc should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:<span class="Sup">3</span>Â </p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Microorganism</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">ATCC<span class="Sup">Â®</span>#</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Zone Diameter Ranges (mm)</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Escherichia coli</span></span></p></td>
<td><p class="First">25922</p></td>
<td><p class="First">29 to 35</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span></p></td>
<td><p class="First">29213</p></td>
<td><p class="First">22 to 28</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Pseudomonas aeruginosa</span></span></p></td>
<td><p class="First">27853</p></td>
<td><p class="First">17 to 23</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Haemophilus influenzae</span></span></p></td>
<td><p class="First">49247</p></td>
<td><p class="First">31 to 39</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae</span></span></p></td>
<td><p class="First">49226</p></td>
<td><p class="First">39 to 51</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span></p></td>
<td><p class="First">49619</p></td>
<td><p class="First">30 to 35</p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">Anaerobic Susceptibility Testing by Agar Dilution:</span></span></span> For anaerobic bacteria, the susceptibility to ceftriaxone as MICs can be determined by standardized test methods.<span class="Sup">6</span> The MIC values obtained should be interpreted according to the following criteria:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Interpretation</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¤16<br>
Â  32<br>
â‰¥64</p></td>
<td><p class="First">(S) Susceptible<br>
(I) Intermediate<br>
(R) Resistant</p></td>
</tr>
</tbody></table>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures. Standardized ceftriaxone powder should provide the following MIC values for the indicated standardized anaerobic dilution<span class="Sup">6</span> testing method:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Method</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Microorganism</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">ATCC<span class="Sup">Â®</span>#</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">MIC (mcg/mL)</span></span></p></td>
</tr>
<tr>
<td>
<p class="First">Agar</p>
<br><p>Â </p>
</td>
<td><p class="First"><span class="Italics"><span class="Emphasis">Bacteroides fragilis</span></span></p></td>
<td><p class="First">25285</p></td>
<td><p class="First">32 to 128</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Italics"><span class="Emphasis">Bacteroides thetaiotaomicron</span></span></p></td>
<td><p class="First">29741</p></td>
<td><p class="First">64 to 256</p></td>
</tr>
</tbody></table>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP, and other antibacterial drugs, Ceftriaxone for Injection, USP, should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Ceftriaxone for Injection, USP, is indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible organisms:</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span></span></span> caused by <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis</span></span> or <span class="Italics"><span class="Emphasis">Serratia marcescens.</span></span>Â </p>
<p><span class="Bold"><span class="Emphasis">Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span></span> caused by <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae, Haemophilus influenzae</span></span> (including beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) or <span class="Italics"><span class="Emphasis">Moraxella catarrhalis</span></span> (including beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p>NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection, USP and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection, USP should be balanced against the potential advantages of parenteral therapy (see <span class="Bold"><span class="Emphasis"><a href="#daec3369-cd35-4fd7-9bdf-fbc0d403e510">CLINICAL STUDIES</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Skin And Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes</span></span>, Viridans group streptococci, <span class="Italics"><span class="Emphasis">Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii,* Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis*</span></span> or <span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </span></span>(<span class="Italics"><span class="Emphasis">complicated and uncomplicated</span></span>) caused by <span class="Italics"><span class="Emphasis">Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii</span></span> or <span class="Italics"><span class="Emphasis">Klebsiella pneumoniae.</span></span>Â </p>
<p><span class="Bold"><span class="Emphasis">Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> </span></span>(<span class="Italics"><span class="Emphasis">cervical/urethral and rectal</span></span>) caused by <span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae,</span></span> including both penicillinase- and nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, and pharyngeal <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by nonpenicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae.</span></span>Â </p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span></span></span> caused by <span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae.</span></span> Ceftriaxone for Injection, USP, like other cephalosporins, has no activity against <span class="Italics"><span class="Emphasis">Chlamydia trachomatis.</span></span> Therefore, when cephalosporins are used in the treatment of patients with <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> and <span class="Italics"><span class="Emphasis">Chlamydia trachomatis</span></span> is one of the suspected pathogens, appropriate antichlamydial coverage should be added.</p>
<p><span class="Bold"><span class="Emphasis">Bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span></span></span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae</span></span> or <span class="Italics"><span class="Emphasis">Klebsiella pneumoniae.</span></span>Â </p>
<p><span class="Bold"><span class="Emphasis">Bone And <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span></span></span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae</span></span> or <span class="Italics"><span class="Emphasis">Enterobacter</span></span> species.</p>
<p><span class="Bold"><span class="Emphasis">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></span></span> caused by <span class="Italics"><span class="Emphasis">Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium</span></span> species (Note: most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">Clostridium difficile</span></span> are resistant) or <span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></span></span> caused by <span class="Italics"><span class="Emphasis">Haemophilus influenzae, Neisseria meningitidis</span></span> or <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span>. Ceftriaxone for Injection, USP has also been used successfully in a limited number of cases of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and shunt <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span>* and <span class="Italics"><span class="Emphasis">Escherichia coli.</span></span>*</p>
<p>*Efficacy for this organism in this organ system was studied in fewer than ten <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><span class="Bold"><span class="Emphasis">Surgical Prophylaxis: </span></span>The preoperative administration of a single 1 gm dose of Ceftriaxone for Injection, USP may reduce the incidence of <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span> in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g.<span class="Italics"><span class="Emphasis">,</span></span> vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span> in high-risk patients, such as those over 70 years of age, with <span class="product-label-link" type="condition" conceptid="194991" conceptname="Calculus of gallbladder with acute cholecystitis">acute cholecystitis</span> not requiring therapeutic antimicrobials, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">obstructive jaundice</span> or common duct bile stones) and in surgical patients for whom <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the operative site would present serious risk (e.g.<span class="Italics"><span class="Emphasis">,</span></span> during coronary artery bypass surgery). Although Ceftriaxone for Injection, USP has been shown to have been as effective as cefazolin in the prevention of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following coronary artery bypass surgery.</p>
<p>When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of Ceftriaxone for Injection, USP provides protection from most <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible organisms throughout the course of the procedure.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Ceftriaxone for injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin class of antibiotics.</p>
<p><span class="Bold"><span class="Emphasis">Neonates (â‰¤28 days)</span></span></p>
<p>Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone for injection. <span class="Italics"><span class="Emphasis">In vitro </span></span>studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a possible risk of bilirubin <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in these patients.</p>
<p><span class="Bold"><span class="Emphasis">Ceftriaxone is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see <a href="#b7899b62-6493-4f98-8f94-189c762fcd9b">CLINICAL PHARMACOLOGY</a>,Â <a href="#b6311635-249a-402a-a80d-1ad1f57b2e18">WARNINGS</a> and <a href="#b3044a83-f607-44c5-9973-6cb59c22411a">DOSAGE AND ADMINISTRATION</a>). </span></span></p>
<p>A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone for injection and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></span></p>
<p>BEFORE THERAPY WITH CEFTRIAXONE FOR INGECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEPHALOSPORINS, PENICILLINS OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGY</span>, PARTICULARLY TO DRUGS. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE THE USE OF SUBCUTANEOUS EPINEPHRINE AND OTHER EMERGENCY MEASURES.</p>
<p>As with other cephalosporins, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> with fatal outcome have been reported, even if a patient is not known to be allergic or previously exposed.</p>
<p><span class="Bold"><span class="Emphasis">Interaction with Calcium-Containing Products</span></span></p>
<p><span class="Bold"><span class="Emphasis">Do not use diluents containing calcium, such as Ringerâ€™s solution or Hartmannâ€™s solution, to reconstitute ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxoneÂ­Â¬calcium can also occur when ceftriaxone for injection is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone for injection must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone for injection and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> between infusions with a compatible fluid.</span></span>Â <span class="Italics"><span class="Emphasis"><span class="Bold">In vitro</span></span></span>Â <span class="Bold"><span class="Emphasis">studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see </span></span><span class="Bold"><span class="Emphasis"><a href="#b7899b62-6493-4f98-8f94-189c762fcd9b">CLINICAL PHARMACOLOGY</a></span></span><span class="Bold"><span class="Emphasis">,Â </span></span><span class="Bold"><span class="Emphasis"><a href="#d7251cf1-c771-403b-ad1a-f4eb33e4910e">CONTRAINDICATIONS</a></span></span><span class="Bold"><span class="Emphasis"> and </span></span><span class="Bold"><span class="Emphasis"><a href="#b3044a83-f607-44c5-9973-6cb59c22411a">DOSAGE AND ADMINISTRATION</a></span></span><span class="Bold"><span class="Emphasis">). </span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">Clostridium difficile</span></span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">Clostridium difficile</span></span></span>Â <span class="Bold"><span class="Emphasis">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ceftriaxone for injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of </span></span><span class="Italics"><span class="Emphasis"><span class="Bold">C.difficile</span></span></span>. </p>
<p><span class="Italics"><span class="Emphasis">C.difficile</span></span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C.difficile</span></span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics"><span class="Emphasis">C.difficile</span></span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics"><span class="Emphasis">C.difficile</span></span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span> </span></span></p>
<p>An immune mediated <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone for injection. Severe cases of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, including fatalities, have been reported during treatment in both adults and children. If a patient develops <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> while on ceftriaxone, the diagnosis of a cephalosporin associated <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> should be considered and ceftriaxone stopped until the etiology is determined. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis">General</span></span></p>
<p>Prescribing ceftriaxone for injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Although transient elevations of BUN and serum creatinine have been observed, at the recommended dosages, the nephrotoxic potential of ceftriaxone for injection is similar to that of other cephalosporins.</p>
<p>Ceftriaxone is excreted via both biliary and renal excretion (see <span class="Bold"><span class="Emphasis"><a href="#b7899b62-6493-4f98-8f94-189c762fcd9b">CLINICAL PHARMACOLOGY</a></span></span>). Therefore, patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> normally require no adjustment in dosage when usual doses of ceftriaxone for injection are administered.</p>
<p>Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, caution should be exercised and the ceftriaxone for injection dosage should not exceed 2 gm daily.</p>
<p>Alterations in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times have occurred rarely in patients treated with ceftriaxone for injection. Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> and <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>) may require monitoring of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time during ceftriaxone for injection treatment. Vitamin K administration (10 mg weekly) may be necessary if the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is prolonged before or during therapy.</p>
<p>Prolonged use of ceftriaxone for injection may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Ceftriaxone for injection should be prescribed with caution in individuals with a history of gastrointestinal disease, especially <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p><span class="Bold"><span class="Emphasis">There have been reports of sonographic abnormalities in the gallbladder of patients treated with ceftriaxone</span></span>Â <span class="Bold"><span class="Emphasis">for injection; some of these patients also had symptoms of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>.</span></span> These abnormalities appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>. The chemical nature of the sonographically detected material has been determined to be predominantly a ceftriaxone-calcium salt. <span class="Bold"><span class="Emphasis">The condition appears to be transient and reversible upon discontinuation of ceftriaxone for injection and institution of conservative management.</span></span> Therefore, ceftriaxone should be discontinued in patients who develop signs and symptoms suggestive of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> and/or the sonographic findings described above.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone for injection. Â Most patients presented with risk factors for <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">biliary stasis</span> and <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">biliary sludge</span> (preceding major therapy, severe illness, total parenteral nutrition). A cofactor role of ceftriaxone for injection related biliary precipitation cannot be ruled out. </p>
<p><span class="Bold"><span class="Emphasis">Information for Patients</span></span></p>
<p>Patients should be counseled that antibacterial drugs including ceftriaxone for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ceftriaxone for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ceftriaxone for injection or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p><span class="Bold"><span class="Emphasis">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Carcinogenesis</span></span></span><span class="Italics"><span class="Emphasis">: </span></span>Considering the maximum duration of treatment and the class of the compound, carcinogenicity studies with ceftriaxone in animals have not been performed. The maximum duration of animal toxicity studies was 6 months.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Mutagenesis</span></span></span><span class="Italics"><span class="Emphasis">: </span></span>Genetic toxicology tests included the Ames test, a micronucleus test and a test for chromosomal aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> cultured <span class="Italics"><span class="Emphasis">in vitro</span></span> with ceftriaxone. Ceftriaxone showed no potential for mutagenic activity in these studies.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Impairment of Fertility</span></span></span><span class="Italics"><span class="Emphasis">: </span></span>Ceftriaxone produced no impairment of fertility when given intravenously to rats at daily doses up to 586 mg/kg/day, approximately 20 times the recommended clinical dose of 2 gm/day.</p>
<p><span class="Bold"><span class="Emphasis">Pregnancy</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Teratogenic Effects</span></span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="Italics"><span class="Emphasis">Pregnancy Category B.</span></span> Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In primates, no embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was demonstrated at a dose approximately 3 times the human dose.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Nonteratogenic Effects</span></span></span><span class="Italics"><span class="Emphasis">:</span></span> In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies with intravenously administered ceftriaxone, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses ofÂ  586 mg/kg/day or less.</p>
<p><span class="Bold"><span class="Emphasis">Nursing Mothers</span></span></p>
<p>Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when ceftriaxone for injection is administered to a nursing woman.</p>
<p><span class="Bold"><span class="Emphasis">Pediatric Use</span></span></p>
<p>Safety and effectiveness of ceftriaxone for injection in neonates, infants and pediatric patients have been established for the dosages described in theÂ <span class="Bold"><span class="Emphasis"><a href="#b3044a83-f607-44c5-9973-6cb59c22411a">DOSAGE AND ADMINISTRATION</a></span></span> section. <span class="Italics"><span class="Emphasis">In vitro</span></span> studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin. Ceftriaxone for injection should not be administered to hyperbilirubinemic neonates, especially prematures (see <span class="Bold"><span class="Emphasis"><a href="#d7251cf1-c771-403b-ad1a-f4eb33e4910e">CONTRAINDICATIONS</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Geriatric Use</span></span></p>
<p>Of the total number of subjects in clinical studies of ceftriaxone for injection, 32% were 60 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </p>
<p>The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patientsÂ  compared to healthy adult subjects and dosage adjustments are not necessary for geriatricÂ  patients with ceftriaxone dosages up to 2 grams per day (see <span class="Bold"><span class="Emphasis"><a href="#b7899b62-6493-4f98-8f94-189c762fcd9b">CLINICAL Â PHARMACOLOGY</a></span></span>). </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Ceftriaxone for injection is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to ceftriaxone for injection therapy or of uncertain etiology, were observed:</p>
<p><span class="Bold"><span class="Emphasis">Local Reactions</span></span> - <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> was 1% overall. <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> was reported in &lt;1% after IV administration. The incidence of warmth, tightness or <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </span></span>- <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.7%). Less frequently reported (&lt;1%) were <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
<p><span class="Bold"><span class="Emphasis">Hematologic </span></span>- <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (6%), <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> (5.1%) and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (2.1%). Less frequently reported (&lt;1%) were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and prolongation of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
<p><span class="Bold"><span class="Emphasis">Gastrointestinal </span></span>- <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.7%). Less frequently reported (&lt;1%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment (see <span class="Bold"><span class="Emphasis"><a href="#b6311635-249a-402a-a80d-1ad1f57b2e18">WARNINGS</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Hepatic </span></span>- elevations of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (3.1%) or SGPT (3.3%). Less frequently reported (&lt;1%) were elevations of alkaline phosphatase and bilirubin.</p>
<p><span class="Bold"><span class="Emphasis">Renal</span></span> - elevations of the BUN (1.2%). Less frequently reported (&lt;1%) were elevations of creatinine and the presence of casts in the urine.</p>
<p><span class="Bold"><span class="Emphasis">Central Nervous System </span></span>- <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> were reported occasionally (&lt;1%).</p>
<p><span class="Bold"><span class="Emphasis">Genitourinary</span></span> - <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> were reported occasionally (&lt;1%).</p>
<p><span class="Bold"><span class="Emphasis">Miscellaneous</span></span> - <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> were reported occasionally (&lt;1%).</p>
<p>Other rarely observed adverse reactions (&lt;0.1%) include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="314617" conceptname="Basophilia">basophilia</span>, biliary lithiasis, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">gallbladder sludge</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="434910" conceptname="Monocytosis">monocytosis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, a decrease in the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, renal precipitations, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>.</p>
<p><span class="Bold"><span class="Emphasis">Postmarketing Experience: </span></span>In addition to the adverse reactions reported during clinical trials, the following adverse experiences have been reported during clinical practice in patients treated with ceftriaxone for injection. Data are generally insufficient to allow an estimate of incidence or to establish causation. </p>
<p>A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone for injection and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates. </p>
<p><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span> â€“ <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>. </p>
<p><span class="Bold"><span class="Emphasis">Genitourinary </span></span>â€“ <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>. </p>
<p><span class="Bold"><span class="Emphasis">Dermatologic</span></span> â€“ <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. As with manyÂ Â  medications, isolated cases of severe cutaneous adverse reactions (<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>,Â  <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> or Lyellâ€™s syndrome/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have beenÂ  reported. </p>
<p><span class="Bold"><span class="Emphasis">Cephalosporin Class Adverse Reactions </span></span></p>
<p>In addition to the adverse reactions listed above which have been observed in patientsÂ  treated with ceftriaxone, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics: </p>
<p><span class="Bold"><span class="Emphasis">Adverse Reactions: </span></span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reaction, renalÂ  dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, hepatic dysfunctionÂ  including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>.</p>
<p><span class="Bold"><span class="Emphasis">Altered Laboratory Tests: </span></span>Positive direct Coombsâ€™ test, false-positive test for urinaryÂ Â  glucose, and elevated LDH. </p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly inÂ  patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced (see <span class="Bold"><span class="Emphasis"><a href="#b3044a83-f607-44c5-9973-6cb59c22411a">DOSAGE AND Â ADMINISTRATION</a></span></span>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug shouldÂ  be discontinued. Anticonvulsant therapy can be given if clinically indicated. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should beÂ symptomatic.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Ceftriaxone for injection may be administered intravenously or intramuscularly.</p>
<p><span class="Bold"><span class="Emphasis">Do not use diluents containing calcium, such as Ringerâ€™s solution or Hartmannâ€™s solution, to reconstitute ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxoneÂ¬Â­calcium can also occur when ceftriaxone for injection is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone for injection must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone for injection and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> between infusions with a compatible fluid (see <a href="#b6311635-249a-402a-a80d-1ad1f57b2e18">WARNINGS</a>). </span></span></p>
<p>There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral). </p>
<p><span class="Bold"><span class="Emphasis">Neonates</span></span></p>
<p>Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection (see <span class="Bold"><span class="Emphasis"><a href="#d7251cf1-c771-403b-ad1a-f4eb33e4910e">CONTRAINDICATIONS</a></span></span>).</p>
<p>Ceftriaxone for injection is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone- calcium (see <span class="Bold"><span class="Emphasis"><a href="#d7251cf1-c771-403b-ad1a-f4eb33e4910e">CONTRAINDICATIONS</a></span></span>). </p>
<p><span class="Bold"><span class="Emphasis">Pediatric Patients</span></span></p>
<p>For the treatment of skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams.</p>
<p>For the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended (see <span class="Bold"><span class="Emphasis"><a href="#f6f5ae63-102e-4f0e-b877-27c84b697992">INDICATIONS AND USAGE</a></span></span>).</p>
<p>For the treatment of serious miscellaneous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days.</p>
<p><span class="Bold"><span class="Emphasis">Adults</span></span></p>
<p>The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. For <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus </span></span>(MSSA), the recommended daily dose is 2 to 4 grams, in order to achieve &gt;90% target attainment. The total daily dose should not exceed 4 grams.</p>
<p>If <span class="Italics"><span class="Emphasis">Chlamydia trachomatis</span></span> is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism.</p>
<p>For the treatment of uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a single intramuscular dose of 250 mg is recommended.</p>
<p>For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended.</p>
<p>Generally, ceftriaxone for injection therapy should be continued for at least 2 days after the signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> have disappeared. The usual duration of therapy is 4 to 14 days; in complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, longer therapy may be required.</p>
<p>When treating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics"><span class="Emphasis">Streptococcus pyogenes</span></span>, therapy should be continued for at least 10 days.</p>
<p>No dosage adjustment is necessary for patients with impairment of renal or hepatic function.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis">Intramuscular Administration</span></span></p>
<p>Reconstitute ceftriaxone for injection with the appropriate diluent (see <span class="Bold"><span class="Emphasis"><a href="#c86398f6-a53e-40b9-8b4f-5c0115aed0be">COMPATIBILITY AND STABILITY</a></span></span>).</p>
<p>Inject diluent into vial, shake vial thoroughly to form solution. Withdraw entire contents of vial into syringe to equal total labeled dose.</p>
<p>After reconstitution, each 1 mL of solution contains approximately 250 mg or 350 mg equivalent of ceftriaxone according to the amount of diluent indicated below. If required, more dilute solutions could be utilized. <span class="Bold"><span class="Emphasis">A 350 mg/mL concentration is not recommended for the 250 mg vial since it may not be possible to withdraw the entire contents.</span></span>Â  </p>
<p>As with all intramuscular preparations, ceftriaxone for injection should be injected well within the body of a relatively large muscle; <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> helps to avoid unintentional injection into a blood vessel.</p>
<table><tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Underline"><span class="Emphasis">Vial Dosage size</span></span></p>
<p>Â </p>
</td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Amount of Diluent to be Added</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Underline"><span class="Emphasis">250 mg/mL</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">350 mg/mL</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">250 mg<br>
500 mg<br>
Â Â Â  1 gm<br>
Â Â Â  2 gm</p></td>
<td><p class="First">0.9 mL<br>
1.8 mL<br>
3.6 mL<br>
7.2 mL</p></td>
<td><p class="First">Â Â Â Â  â€”<br>
Â Â  1 mL<br>
2.1 mL<br>
4.2 mL</p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">Intravenous Administration</span></span></p>
<p>Ceftriaxone for injection should be administered intravenously by infusion over a period of 30 minutes. Concentrations between 10 mg/mL and 40 mg/mL are recommended; however, lower concentrations may be used if desired. Reconstitute vials or â€œpiggybackâ€? bottles with an appropriate IV diluent (see <span class="Bold"><span class="Emphasis"><a href="#c86398f6-a53e-40b9-8b4f-5c0115aed0be">COMPATIBILITY AND STABILITY</a></span></span>).</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Vial Dosage Size</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Amount of Diluent to be Added</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">250 mg<br>
500 mg<br>
Â Â Â  1 gm<br>
Â Â Â  2 gm</p></td>
<td><p class="First">2.4 mL<br>
4.8 mL<br>
9.6 mL<br>
19.2 mL</p></td>
</tr>
</tbody></table>
<p>After reconstitution, each 1mL of solution contains approximately 100 mg equivalent of ceftriaxone. Withdraw entire contents and dilute to the desired concentration with the appropriate IV diluent.</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Underline"><span class="Emphasis">Piggyback Bottle Dosage Size</span></span></p></td>
<td><p class="First"><span class="Underline"><span class="Emphasis">Amount of Diluent to be Added</span></span></p></td>
</tr>
<tr class="Last">
<td><p class="First">1 gm<br>
2 gm</p></td>
<td><p class="First">10 mL<br>
20 mL</p></td>
</tr>
</tbody></table>
<p>After reconstitution, further dilute to 50 mL or 100 mL volumes with the appropriate IV diluent.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Ceftriaxone has been shown to be compatible with Flagyl<span class="Sup">Â®</span> IV (metronidazole hydrochloride). The concentration should not exceed 5 to 7.5 mg/mL metronidazole hydrochloride with ceftriaxone 10 mg/mL as an admixture. The admixture is stable for 24 hours at room temperature only in 0.9% sodium chloride injection or 5% dextrose in water (D5W). No compatibility studies have been conducted with the Flagyl<span class="Sup">Â®</span> IV RTU<span class="Sup">Â®</span> (metronidazole) formulation or using other diluents. Metronidazole at concentrations greater than 8 mg/mL will precipitate. Do not refrigerate the admixture as precipitation will occur.</p>
<p>Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures. When any of these drugs are to be administered concomitantly with ceftriaxone by intermittent intravenous infusion, it is recommended that they be given sequentially, with thorough <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the intravenous lines (with one of the compatible fluids) between the administrations.</p>
<p><span class="Bold"><span class="Emphasis">Do not use diluents containing calcium, such as Ringerâ€™s solution or Hartmannâ€™s solution, to reconstitute ceftriaxone for injection vials or to further dilute a reconstituted vial for IV administration. Particulate formation can result. </span></span></p>
<p>Ceftriaxone for injection solutions should <span class="Italics"><span class="Emphasis">not</span></span> be physically mixed with or piggybacked into solutions containing other antimicrobial drugs or into diluent solutions other than those listed above, due to possible incompatibility (see <span class="Bold"><span class="Emphasis"><a href="#b6311635-249a-402a-a80d-1ad1f57b2e18">WARNINGS</a></span></span>).</p>
<p>Ceftriaxone for injection sterile powder should be stored at 20Â° to 25Â°C (68Â° to 77Â°F) [<span class="Bold"><span class="Emphasis">See USP Controlled Room Temperature</span></span>] and protected from light. After reconstitution, protection from normal light is not necessary. The color of solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.</p>
<p>Ceftriaxone for injection <span class="Italics"><span class="Emphasis">intramuscular</span></span> solutions remain stable (loss of potency less than 10%) for the following time periods:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First">Diluent</p></td>
<td><p class="First">Concentration<br>
mg/mL</p></td>
<td><p class="First">Storage</p></td>
</tr>
<tr>
<td><p class="First">Room Temp.<br>
(25Â°C)</p></td>
<td><p class="First">Refrigerated<br>
(4Â°C)</p></td>
</tr>
<tr>
<td><p class="First">Sterile Water for Injection</p></td>
<td><p class="First">Â Â Â Â Â Â Â  100<br>
250, 350</p></td>
<td><p class="First">2 days<br>
24 hours</p></td>
<td><p class="First">10 days<br>
3 days</p></td>
</tr>
<tr>
<td><p class="First">0.9% Sodium ChlorideÂ <br>
Â Â Â  Solution</p></td>
<td><p class="First">Â Â Â Â Â Â Â  100<br>
250, 350</p></td>
<td><p class="First">2 days<br>
24 hours</p></td>
<td><p class="First">10 days<br>
3 days</p></td>
</tr>
<tr>
<td><p class="First">5% Dextrose Solution</p></td>
<td><p class="First">Â Â Â Â Â Â  100<br>
250, 350</p></td>
<td><p class="First">2 days<br>
24 hours</p></td>
<td><p class="First">10 days<br>
3 days</p></td>
</tr>
<tr>
<td><p class="First">Bacteriostatic Water + 0.9%<br>
Â Â Â  Benzyl Alcohol</p></td>
<td><p class="First">Â Â Â Â Â Â Â  100<br>
250, 350</p></td>
<td><p class="First">24 hours<br>
24 hours</p></td>
<td><p class="First">10 days<br>
3 days</p></td>
</tr>
<tr class="Last">
<td><p class="First">1% Lidocaine Solution<br>
Â Â Â  (without epinephrine)</p></td>
<td><p class="First">Â Â Â Â Â Â  100<br>
250, 350</p></td>
<td><p class="First">24 hours<br>
24 hours</p></td>
<td><p class="First">10 days<br>
3 days</p></td>
</tr>
</tbody></table>
<p>Ceftriaxone for injection <span class="Italics"><span class="Emphasis">intravenous</span></span> solutions, at concentrations of 10, 20 and 40 mg/mL, remain stable (loss of potency less than 10%) for the following time periods stored in glass or PVC containers:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First">Diluent</p></td>
<td><p class="First">Storage</p></td>
</tr>
<tr>
<td><p class="First">Room Temp.<br>
(25Â°C)</p></td>
<td><p class="First">Refrigerated<br>
(4Â°C)</p></td>
</tr>
<tr>
<td><p class="First">Sterile Water</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">10 days</p></td>
</tr>
<tr>
<td><p class="First">0.9% Sodium Chloride Solution</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">10 days</p></td>
</tr>
<tr>
<td><p class="First">5% Dextrose Solution</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">10 days</p></td>
</tr>
<tr>
<td><p class="First">10% Dextrose Solution</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">10 days</p></td>
</tr>
<tr>
<td><p class="First">5% Dextrose + 0.9% Sodium Chloride Solution*</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">Incompatible</p></td>
</tr>
<tr>
<td><p class="First">5% Dextrose + 0.45% Sodium Chloride Solution</p></td>
<td><p class="First">2 days</p></td>
<td><p class="First">Incompatible</p></td>
</tr>
<tr class="Last"><td><p class="First">*Data available for 10 to 40 mg/mL concentrations in this diluent in PVC containers only.</p></td></tr>
</tbody></table>
<p>Similarly, ceftriaxone for injection <span class="Italics"><span class="Emphasis">intravenous</span></span> solutions, at concentrations of 100 mg/mL, remain stable in the IV piggyback glass containers for the above specified time periods.</p>
<p>The following <span class="Italics"><span class="Emphasis">intravenous</span></span> ceftriaxone for injection solutions are stable at room temperature (25Â°C) for 24 hours, at concentrations between 10 mg/mL and 40 mg/mL: Sodium Lactate (PVC container), 10% Invert Sugar (glass container), 5% Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> (glass container), Freamine III (glass container), Normosol-M in 5% Dextrose (glass and PVC containers), Ionosol-B in 5% Dextrose (glass container), 5% Mannitol (glass container), 10% Mannitol (glass container).</p>
<p>After the indicated stability time periods, unused portions of solutions should be discarded.</p>
<p>NOTE: Parenteral drug products should be inspected visually for particulate matter before administration.</p>
<p>Ceftriaxone for injection reconstituted with 5% Dextrose or 0.9% Sodium Chloride solution at concentrations between 10 mg/mL and 40 mg/mL, and then stored in frozen state (-20Â°C) in PVC or polyolefin containers, remains stable for 26 weeks. </p>
<p>Frozen solutions of ceftriaxone for injection should be thawed at room temperature before use. After thawing, unused portions should be discarded. <span class="Bold"><span class="Emphasis">DO NOT REFREEZE.</span></span>Â </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-13"></a><p></p>
<h1>ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY</h1>
<p class="First"></p>
<p>Concretions consisting of the precipitated calcium salt of ceftriaxone have been found in the gallbladder bile of dogs and baboons treated with ceftriaxone.</p>
<p>These appeared as a gritty sediment in dogs that received 100 mg/kg/day for 4 weeks. A similar phenomenon has been observed in baboons but only after a protracted dosing period (6 months) at higher dose levels (335 mg/kg/day or more). The likelihood of this occurrence in humans is considered to be low, since ceftriaxone has a greater plasma half-life in humans, the calcium salt of ceftriaxone is more soluble in human gallbladder bile and the calcium content of human gallbladder bile is relatively low.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Ceftriaxone for Injection, USP is supplied as a sterile crystalline powder in glass vials and piggyback bottles. The following packages are available :</p>
<p>Vials containing 250 mg equivalent of ceftriaxone. Box of 1 (NDC 60505-0750-0) and box of 10 (NDC 60505-0750-4).Â  </p>
<p>Vials containing 500 mg equivalent of ceftriaxone. Box of 1 (NDC 60505-0751-0) and box of 10 (NDC 60505-0751-4).Â  </p>
<p>Vials containing 1 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-0752-0) and box of 10 (NDC 60505-0752-4). </p>
<p>Vials containing 2 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-0753-0) and box of 10 (NDC 60505-0753-4).</p>
<p>Piggyback bottles containing 1 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-6087-1).</p>
<p>Piggyback bottles containing 2 gm equivalent of ceftriaxone. Box of 1 (NDC 60505-6088-1).</p>
<p>NOTE: Ceftriaxone for Injection, USP sterile powder should be stored at 20Â° to 25Â°C Â (68Â°Â  to 77Â°F) [<span class="Bold"><span class="Emphasis">See USP Controlled Room Temperature</span></span>] and protected from light.</p>
<p>Flagyl<span class="Sup">Â®</span> is a registered trademark of G.D. Searle LLC.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-15"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p><span class="Italics"><span class="Emphasis">Clinical Trials in Pediatric Patients With Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>:</span></span> In two adequate and well-controlled U.S. clinical trials a single IM dose of ceftriaxone was compared with a 10 day course of oral antibiotic in pediatric patients between the ages ofÂ 3 months and 6 years. The clinical cure rates and statistical outcome appear in the table below:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First">Â </p></td>
<td><p class="First"><span class="Bold"><span class="Emphasis">Â Â Â Â  Clinical Efficacy in Evaluable Population</span></span></p></td>
</tr>
<tr>
<td><p class="First">Study Day</p></td>
<td><p class="First">Ceftriaxone<br>
Single Dose</p></td>
<td><p class="First">Comparator-<br>
10 Days of<br>
Oral Therapy</p></td>
<td><p class="First">95%<br>
Confidence<br>
Interval</p></td>
<td><p class="First">Statistical<br>
Outcome</p></td>
</tr>
<tr>
<td><p class="First">Study 1Â - U.S.</p></td>
<td><p class="First">amoxicillin/clavulanate</p></td>
</tr>
<tr>
<td><p class="First">14</p></td>
<td><p class="First">74% (220/296)</p></td>
<td><p class="First">82% (247/302)</p></td>
<td><p class="First">(-14.4%, - 0.5%)</p></td>
<td><p class="First">Ceftriaxone is lower<br>
Â than control at<br>
Â study day 14 and 28.</p></td>
</tr>
<tr>
<td><p class="First">28</p></td>
<td><p class="First">58% (167/288)</p></td>
<td><p class="First">67% (200/297)</p></td>
<td><p class="First">(-17.5%, - 1.2%)</p></td>
</tr>
<tr>
<td><p class="First">Study 2Â - U.S.<span class="Sup">7</span></p></td>
<td><p class="First">TMP-SMZ</p></td>
</tr>
<tr>
<td><p class="First">14</p></td>
<td><p class="First">54% (113/210)</p></td>
<td><p class="First">60% (124/206)</p></td>
<td><p class="First">(-16.4%, 3.6%)</p></td>
<td><p class="First">Ceftriaxone is<br>
equivalent to control<br>
Â at study day 14 and 28.</p></td>
</tr>
<tr class="Last">
<td><p class="First">28</p></td>
<td><p class="First">35% (73/206)</p></td>
<td><p class="First">45% (93/205)</p></td>
<td><p class="First">(-19.9%, 0.0%)</p></td>
</tr>
</tbody></table>
<p>An open-label bacteriologic study of ceftriaxone without a comparator enrolled 108 pediatric patients, 79 of whom had positive baseline cultures for one or more of the common pathogens. The results of this study are tabulated as follows:</p>
<p>Week 2 and 4 Bacteriologic Eradication Rates in the Per Protocol Analysis in the Roche Bacteriologic Study by pathogen:</p>
<table><tbody class="Headless">
<tr class="First">
<td><p class="First">Â </p></td>
<td>
<p class="First">Study Day</p>
<p>13 to 15</p>
</td>
<td>
<p class="First">Study Day</p>
<p>30+2</p>
</td>
</tr>
<tr>
<td><p class="First">Organism</p></td>
<td><p class="First">No.<br>
Analyzed</p></td>
<td><p class="First">No.<br>
Erad. (%)</p></td>
<td><p class="First">No.<br>
Analyzed</p></td>
<td>
<p class="First">No.<br>
Erad. (%)</p>
<p>Â </p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span></p></td>
<td><p class="First">38</p></td>
<td><p class="First">32 (84)</p></td>
<td><p class="First">35</p></td>
<td><p class="First">25 (71)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics"><span class="Emphasis">Haemophilus influenzae</span></span></p></td>
<td><p class="First">33</p></td>
<td><p class="First">28 (85)</p></td>
<td><p class="First">31</p></td>
<td><p class="First">22 (71)</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Italics"><span class="Emphasis">Moraxella catarrhalis</span></span></p></td>
<td><p class="First">15</p></td>
<td><p class="First">12 (80)</p></td>
<td><p class="First">15</p></td>
<td><p class="First">Â  9 (60)</p></td>
</tr>
</tbody></table>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-16"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<ol>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics"><span class="Emphasis">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;</span></span> Approved Standard-Eighth Edition. CLSI document M07-A8. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087, 2009. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics"><span class="Emphasis">Performance Standards for Antimicrobial Susceptibility Testing;</span></span> Twentieth Informational Supplement. CLSI document M100-S20. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087, 2010. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics"><span class="Emphasis">Performance Standards for Antimicrobial Disk Susceptibility Tests; </span></span>Approved Standard-Tenth Edition. CLSI document M02-A10. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087, 2009. </li>
<li>Burgess DS, Frei CR, Lewis II JS, et al. The contribution of pharmacokinetic-pharmacodynamic modeling with Monte Carlo simulation to the development of susceptibility breakpoints for <span class="Italics"><span class="Emphasis">Neisseria meningitidis</span></span>. Clin Microbiol Infect. 2007;13:33-39. </li>
<li>Jorgensen JH, Crawford SA, Fulcher LC, et al. Multilaboratory evaluation of disk diffusion antimicrobial susceptibility testing of Neisseria meningitidis isolates. J Clin Microbiol. 2006;44(5):1744-1754. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Seventh Edition. CLSI document M11-A7. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087, 2007. </li>
<li>Barnett ED, Teele DW, Klein JO, et al. <span class="Italics"><span class="Emphasis">Comparison of Ceftriaxone and Trimethoprim-Sulfamethoxazole for Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>. </span></span>Pediatrics. Vol. 99, No. 1, January 1997. </li>
</ol>
<p>Â </p>
<p>Mfg. by:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mfg. for:</p>
<p><span class="Bold"><span class="Emphasis">Hospira Healthcare India Pvt. Ltd.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Apotex Corp.</span></span></p>
<p>Irungattukottai - 602 105, India Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Weston, FL 33326</p>
<p>Â </p>
<p>DATE OF REVISION: JULY 2011</p>
<p>948026009</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Ceftriaxone </p>
<p><br></p>
<p>GENERIC: Ceftriaxone Sodium</p>
<p><br></p>
<p>DOSAGE: INJECTION, POWDER, FOR SOLUTION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 52125-774-20</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>CEFTRIAXONE SODIUM 250mg in 1</li></ul>
<p><br></p>
<p>PACKAGING: 100  in 1 CARTON</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0faaee8c-30f6-4715-a9b6-7978da7c1ec8&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0faaee8c-30f6-4715-a9b6-7978da7c1ec8&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFTRIAXONEÂ 		
					</strong><br><span class="contentTableReg">ceftriaxone sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-774(NDC:60505-0750)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFTRIAXONE SODIUM</strong> (CEFTRIAXONE) </td>
<td class="formItem">CEFTRIAXONE</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-774-20</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065230</td>
<td class="formItem">12/17/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>49c49b79-a384-45e6-ac3c-c73d2b01aeec</div>
<div>Set id: 0faaee8c-30f6-4715-a9b6-7978da7c1ec8</div>
<div>Version: 1</div>
<div>Effective Time: 20131217</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
